Results 81 to 90 of about 1,340,339 (303)

Adverse events and in-hospital mortality: an analysis of all deaths in a Norwegian health trust during 2011

open access: yesBMC Health Services Research, 2017
Background The estimated number of in-hospitals deaths due to adverse events is often different when using data from deceased patients compared with that of a population experiencing adverse events.
Hans Flaatten   +8 more
doaj   +1 more source

Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. [PDF]

open access: yes, 2016
ObjectiveTo compare different blood pressure (BP) levels in their association with the risk of renal outcomes in type 1 diabetes and to determine whether an intensive glycemic control strategy modifies this association.Research design and methodsWe ...
Gitelman, Stephen E   +5 more
core   +2 more sources

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade

open access: yesMolecular Oncology, EarlyView.
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley   +1 more source

Topical treatment of peripheral neuropathic pain: applying the evidence [PDF]

open access: yes, 2017
Patients with peripheral neuropathic pain (NP) may only achieve partial pain relief with currently recommended first-line oral treatments, which are also associated with systemic adverse events.
Cruccu, Giorgio, Sommer, Claudia
core   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

open access: yesMolecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková   +14 more
wiley   +1 more source

Fathers’ parenting, adverse life events, and adolescents’ emotional and eating disorder symptoms: the role of emotion regulation [PDF]

open access: yes, 2008
Purpose: To investigate the role of emotion regulation in the relation between fathers’ parenting (specifically warmth, behavioral control and psychological control) and adolescents’ emotional and eating disorder symptoms, after adjustment for controls ...
Flouri, Eirini, McEwen, Ciara
core   +4 more sources

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

open access: yesMolecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim   +11 more
wiley   +1 more source

Rural Hospital Nursing Skill Mix and Work Environment Associated with Frequency of Adverse Events. [PDF]

open access: yes, 2019
Introduction: Though rural hospitals serve about one fifth of the United States (U.S.), few studies have investigated relationships among nursing resources and rural hospital adverse events.
Lake, Eileen T.   +3 more
core   +1 more source

Stability of a Giant Connected Component in a Complex Network [PDF]

open access: yes, 2018
We analyze the stability of the network's giant connected component under impact of adverse events, which we model through the link percolation. Specifically, we quantify the extent to which the largest connected component of a network consists of the ...
Alderson, David L.   +6 more
core   +2 more sources

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

open access: yesMolecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy